United States — Food and Drug Administration & Knight Therapeutics

United States — Food and Drug Administration: The United States — Food and Drug Administration expressed concerns to Knight Therapeutics about the adequacy of its clinical development program for relacorilant, which is a key factor in the lawsuit against Knight Therapeutics.

Knight Therapeutics: Knight Therapeutics is facing a federal securities lawsuit for allegedly failing to disclose concerns from the FDA regarding its drug candidate, relacorilant, which could lead to a rejection of its New Drug Application. This event negatively impacts its stock price and reputation.